Postoperative ComplicationsPRECiousNCT02102217
the PRECious Trial: PREdiction of Complications
A study testing PRECious in people with Postoperative Complications, run by Amsterdam UMC, location VUmc at 1 site in Netherlands.
Trial summary
20% of patients who undergo major abdominal surgery will have a major complication, which requires invasive treatment and is associated with increased mortality, morbidity, hospital stay and intensive care stay. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Postoperative Complications
- What is being tested?
- PRECious
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 525 participants
- Where
- 1 siteNetherlands
- Study dates
- Dec 2015to Sep 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age equal to or above 18 years
- Planned elective MAS
- Written and oral informed consent
Who cannot join
- Acute MAS
- ASA classification equal to four or higher
- Insufficient Dutch language skills
- contrast allergies
- glomerular filtration rate (GFR) < 60 ml/min/1,73m2
Trial locations and contacts
1 site in 1 country.
About this study
Official title: PREdiction of Complications: A Step-up Approach, CRP First Followed by CT-scan Imaging to Ensure Quality Control After Major Abdominal Surgery
20% of patients who undergo major abdominal surgery will have a major complication, which requires invasive treatment and is associated with increased mortality, morbidity, hospital stay and intensive care stay. A quality control algorithm after Major Abdominal Surgery (MAS) aimed at early identification of patients at risk of developing major complications can decrease associated morbidity and mortality. Literature studies show promising results for C-reactive protein as an early marker for postoperative complications, however clinical significance has yet to be determined. Here the investigators propose a randomized clinical trial in order to determine the effect of postoperative monitoring with standardized CRP measurements on postoperative morbidity and mortality, if CRP levels exceed 140 mg/L additional CT-scan imaging will be conducted.
Read the detailed description
Major Abdominal Surgery (MAS) may be defined as a surgical resection performed on colorectal, hepato-pancreatico-biliary and upper-GI organs with either primary anastomosis and/or ostomy. In patients undergoing MAS postoperative complications are reported in up to 40% of patients. Around 20% of all MAS patients have a major complication, which requires invasive treatment such as reoperation, percutaneous drainage and intensive care admission. Major complications further increase morbidity and mortality after major abdominal surgery, leading to longer intensive care and hospital stay, unplanned open procedures and creation of ostomies and possible increased cancer recurrence rates and costs.
In current postoperative practice median time to clinical diagnosis of a postoperative complication is approximately eight days. A delay in diagnosis of complications increases morbidity and mortality related to major complications. Whereas early diagnosis of postoperative septic complications, before clinical deterioration, is associated with a decrease in the associated morbidity and mortality. An early detection of septic complications is challenging and may clinically and serologically, as well while using imaging techniques, be hard to distinguish from the physiological and postoperative systemic inflammatory response syndrome (SIRS). Furthermore clinical risk assessment appears to have a low predictive value for major complications such as anastomotic leak. This further stresses the need for a standardized Quality Control algorithm after MAS.
Noteworthy is that nowadays no standard Quality Control tests or protocols are available after MAS to differentiate between a normal and a complicated postoperative course.
In the search for a marker in early diagnosis of postoperative complications several biomarkers have been assessed, such as interleukin 6 (IL-6), Tumour necrosis factor α (TNF-α), procalcitonin, white blood cell count (WBC) and C-reactive protein (CRP).
WBC showed no significant differences between patients with an uncomplicated versus complicated postoperative course. WBC is therefore not useful in a standardized quality control algorithm. Procalcitonin, IL-6 and TNF-α have been assessed as markers of postoperative sepsis. However, compared to CRP they achieve similar results in predicting major complications after MAS. Moreover, taking into account the higher cost and limited availability of testing for procalcitonin, IL-6 and TNF-α levels, we further focussed on the use of CRP in a postoperative standardized quality control algorithm.
CRP is well established as a marker for infections and complications and showed promising results . It is an acute phase protein, synthesized in the liver, under stimulation of IL-6 and TNF-α in inflammatory processes, which amongst others enhances phagocytosis of bacteria by macrophages. In healthy individuals, CRP level is <1 mg/L. In mild inflammation it can rapidly reach over 40 mg/L and even over 400 mg/L have been detected in severe inflammatory response, sepsis or burns. CRP levels are also raised as a consequence of operative trauma, and it is even suggested that the level of postoperative CRP is proportional to the length of the operation, amount of operative trauma and intra-operative complications . A peak in postoperative CRP levels is observed 48-72 hours after surgery. In uneventful cases, the levels decrease after this peak. Furthermore, plasma half-life of CRP is 19 hours and is independent of diet, diurnal rhythm or organ function. Circulating CRP levels are therefore only determined by their rate of synthesis. Based on these characteristics, CRP might be a promising valuable marker for the grade of inflammation related to postoperative complications.
Several studies have assessed the use of CRP as a marker for postoperative complications after major abdominal surgery. Established cut-off CRP levels serving as markers for infective complications range from 140 mg/L to 170 mg/L on postoperative day (POD) 3. Regarding anastomotic leakage in colorectal patients, the cut-off for CRP levels have been proposed at 190 mg/L on POD 3and 125 mg/l for POD 4. Published variations in cut-offs for CRP levels are related to differing positive and negative predictive values.
The largest retrospective series included 1187 patients that had undergone colorectal surgery. They calculated a cut-off of 123 mg/L as a marker for all septic complications, yet they did not differentiate between minor and major complications. A recent meta-analysis established a cut-off of 172 mg/l on POD 3 as a marker for anastomotic leakage. Definitions regarding anastomotic leak vary widely among literature, which limits reproducibility and excludes patients that require re-intervention for other complications. Therefore our interest lies in diagnosing all major complications that require invasive treatment, as classified by grades 3-5 in the Clavien Dindo classification.
Based on our own systematic review and pooled-analysis of 1427 patients that underwent MAS, a level of 140 mg/l is proposed as cut-off for postoperative days 3,4 and 5 as a marker for major complications, with an overall sensitivity of 81,7% and a sensitivity of 61,6% Serum CRP is non-specific for location, thus additional imaging is required. Computed Tomography (CT) is the current imaging modality of choice. In our retrospective data, CT-scans showed a sensitivity of 91,7% and specificity of 100% for diagnosis of major complications, this is conformed in literature. Moreover, in the study conducted by Eckmann et al. CT-scan imaging showed a sensitivity of 97%. Another recent study established CT-scan imaging as the preferred modality in diagnosis of anastomotic leakage.
In 2008, Den Dulk et al. implemented a standardized scoring system for the clinical status of patients undergoing colorectal surgery. With this system they decreased the time between surgery and diagnosis of anastomotic leakage from 8 to 6 days, thereby decreasing mortality from 39% to 24% (p=0,24). Further supporting the role for a standardized postoperative quality control algorithm following MAS. However the search for an optimal algorithm continues.
CRP and CT scanning have shown to be able to differentiate between uncomplicated and complicated postoperative courses. Currently their use is only on demand. The here presented PRECious protocol is a postoperative Quality Control algorithm, which aims at early diagnosis and treatment of patients with major complications.
- Conditions
- Postoperative Complications
- Being tested
- PRECious
- Keywords
- Major Abdominal Surgery, C-reactive protein, Computed Tomography, Quality Control, Postoperative complications
- Medical subject headings
- Postoperative Complications
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PRECiousProcedure or surgery
Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
| Study group | Role | What they receive |
|---|---|---|
| Precious arm | Experimental | Postoperative controls according to the PRECious protocol, which entails standardized measurement of CRP levels on postoperative day three, four and five. If CRP levels exceed 140 mg/l additional CT-scan imaging will be conducted. Receives: Procedure: PRECious |
| Control | No intervention | Standard postoperative controls. Additional testing will only be conducted on demand. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Morbidity and mortality after major complications
Combined Primary outcome, entailing both:
- Mortality; during 12 month follow-up
- Morbidity associated with major complications and after reoperation within 12 months after index operation. Including: Fistula, Wound dehiscence/incisional hernia/open abdomen, bowel obstruction or herniation, abscess, abdominal compartment syndrome, perforation of visceral organ, unplanned enterostomy, enterostomy dysfunction due to prolapse, stenosis or retraction, myocardial infarction, pulmonary embolus, respiratory insufficiency; necessitating mechanical ventilation, cerebrovascular accident, renal failure, urosepsis; urinary tract infection with positive urine and blood cultures and circulatory shock, upper GI bleeding needing intervention of any type, intra-abdominal bleeding, anastomotic leak after relaparotomy
Measured: one year
Secondary outcomes (5)
Quality of life questionnaires
Quality of life questionnaires will be conducted 3 and 5 days postoperatively, and during follow-up after 3 and 12 months. Questionnaires consist of the EQ-5D (EuroQol), SF-36 (Short-Form 36) and GIQLI (GastroInstestinal Quality of Life Index).
Measured: 3,5 days, 3 and 12 months postoperatively
Add-on value of CRP
During rounds, before CRP levels are measured, the attending physician grades patients on a scale of 1 to 10 (one being a healthy patient, ten being a patient at risk of acute death).
Measured: postoperative days 3,4 and 5
Length of stay
total length of hospital stay in days (n)
Measured: Up to one year after randomization
Length of Intensive Care admission
total stay on the Intensive Care Unit in days (n)
Measured: up to one year after randomization
Cost-efficiency
Total costs in both study arms regarding surgery, admission, additional testing, re-interventions
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2014 (estimated)
- Study startDec 2015
- Primary completionMay 2020
- Study completionSep 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Postoperative ComplicationsStudies of the same condition, open and under way.
- More trials run by Amsterdam UMC, location VUmcThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 525 participants (actual)
Sponsor and investigators
- Lead sponsor
- Amsterdam UMC, location VUmc
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, J. Straatman, Amsterdam UMC, location VUmc
- Investigators
- Jennifer Straatman, MD, Principal investigator, VU Medisch CentrumDonald van der Peet, MD, PhD, Principal investigator, VU Medisch Centrum
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02102217
- Sponsor's protocol ID
- Pro14/23
- Acronym
- PRECious
- Status last verified
- Nov 2020
- First submitted
- 19 Mar 2014
- Last updated
- 6 Nov 2020
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Straatman J, Cuesta MA, Schreurs WH, Dwars BJ, Cense HA, Rijna H, Sonneveld DJ, den Boer FC, de Lange-de Klerk ES, van der Peet DL. The PRECious trial PREdiction of Complications, a step-up approach, CRP first followed by CT-scan imaging to ensure quality control after major abdominal surgery: study protocol for a stepped-wedge trial. Trials. 2015 Aug 28;16:382. doi: 10.1186/s13063-015-0903-y.
PubMed 26314740
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PREdiction of Complications: A Step-up Approach, CRP First Followed by CT-scan Imaging to Ensure Quality Control After Major Abdominal Surgery
- ClinicalTrials.gov ID
- NCT02102217
- Acronym / sponsor ID
- PRECious / Pro14/23
- Conditions
- Postoperative Complications
- Keywords
- Major Abdominal Surgery, C-reactive protein, Computed Tomography, Quality Control, Postoperative complications
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 525 participants (actual)
- Lead sponsor
- Amsterdam UMC, location VUmcUniversity, hospital or other
- Study start
- Dec 2015
- Primary completion
- May 2020 (actual)
- Study completion
- Sep 2020 (actual)
- First posted
- 2 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
20% of patients who undergo major abdominal surgery will have a major complication, which requires invasive treatment and is associated with increased mortality, morbidity, hospital stay and intensive care stay. A quality control algorithm after Major Abdominal Surgery (MAS) aimed at early identification of patients at risk of developing major complications can decrease associated morbidity and mortality. Literature studies show promising results for C-reactive protein as an early marker for postoperative complications, however clinical significance has yet to be determined. Here the investigators propose a randomized clinical trial in order to determine the effect of postoperative monitoring with standardized CRP measurements on postoperative morbidity and mortality, if CRP levels exceed 140 mg/L additional CT-scan imaging will be conducted.
Detailed description
Major Abdominal Surgery (MAS) may be defined as a surgical resection performed on colorectal, hepato-pancreatico-biliary and upper-GI organs with either primary anastomosis and/or ostomy. In patients undergoing MAS postoperative complications are reported in up to 40% of patients. Around 20% of all MAS patients have a major complication, which requires invasive treatment such as reoperation, percutaneous drainage and intensive care admission. Major complications further increase morbidity and mortality after major abdominal surgery, leading to longer intensive care and hospital stay, unplanned open procedures and creation of ostomies and possible increased cancer recurrence rates and costs.
In current postoperative practice median time to clinical diagnosis of a postoperative complication is approximately eight days. A delay in diagnosis of complications increases morbidity and mortality related to major complications. Whereas early diagnosis of postoperative septic complications, before clinical deterioration, is associated with a decrease in the associated morbidity and mortality. An early detection of septic complications is challenging and may clinically and serologically, as well while using imaging techniques, be hard to distinguish from the physiological and postoperative systemic inflammatory response syndrome (SIRS). Furthermore clinical risk assessment appears to have a low predictive value for major complications such as anastomotic leak. This further stresses the need for a standardized Quality Control algorithm after MAS.
Noteworthy is that nowadays no standard Quality Control tests or protocols are available after MAS to differentiate between a normal and a complicated postoperative course.
In the search for a marker in early diagnosis of postoperative complications several biomarkers have been assessed, such as interleukin 6 (IL-6), Tumour necrosis factor α (TNF-α), procalcitonin, white blood cell count (WBC) and C-reactive protein (CRP).
WBC showed no significant differences between patients with an uncomplicated versus complicated postoperative course. WBC is therefore not useful in a standardized quality control algorithm. Procalcitonin, IL-6 and TNF-α have been assessed as markers of postoperative sepsis. However, compared to CRP they achieve similar results in predicting major complications after MAS. Moreover, taking into account the higher cost and limited availability of testing for procalcitonin, IL-6 and TNF-α levels, we further focussed on the use of CRP in a postoperative standardized quality control algorithm.
CRP is well established as a marker for infections and complications and showed promising results . It is an acute phase protein, synthesized in the liver, under stimulation of IL-6 and TNF-α in inflammatory processes, which amongst others enhances phagocytosis of bacteria by macrophages. In healthy individuals, CRP level is <1 mg/L. In mild inflammation it can rapidly reach over 40 mg/L and even over 400 mg/L have been detected in severe inflammatory response, sepsis or burns. CRP levels are also raised as a consequence of operative trauma, and it is even suggested that the level of postoperative CRP is proportional to the length of the operation, amount of operative trauma and intra-operative complications . A peak in postoperative CRP levels is observed 48-72 hours after surgery. In uneventful cases, the levels decrease after this peak. Furthermore, plasma half-life of CRP is 19 hours and is independent of diet, diurnal rhythm or organ function. Circulating CRP levels are therefore only determined by their rate of synthesis. Based on these characteristics, CRP might be a promising valuable marker for the grade of inflammation related to postoperative complications.
Several studies have assessed the use of CRP as a marker for postoperative complications after major abdominal surgery. Established cut-off CRP levels serving as markers for infective complications range from 140 mg/L to 170 mg/L on postoperative day (POD) 3. Regarding anastomotic leakage in colorectal patients, the cut-off for CRP levels have been proposed at 190 mg/L on POD 3and 125 mg/l for POD 4. Published variations in cut-offs for CRP levels are related to differing positive and negative predictive values.
The largest retrospective series included 1187 patients that had undergone colorectal surgery. They calculated a cut-off of 123 mg/L as a marker for all septic complications, yet they did not differentiate between minor and major complications. A recent meta-analysis established a cut-off of 172 mg/l on POD 3 as a marker for anastomotic leakage. Definitions regarding anastomotic leak vary widely among literature, which limits reproducibility and excludes patients that require re-intervention for other complications. Therefore our interest lies in diagnosing all major complications that require invasive treatment, as classified by grades 3-5 in the Clavien Dindo classification.
Based on our own systematic review and pooled-analysis of 1427 patients that underwent MAS, a level of 140 mg/l is proposed as cut-off for postoperative days 3,4 and 5 as a marker for major complications, with an overall sensitivity of 81,7% and a sensitivity of 61,6% Serum CRP is non-specific for location, thus additional imaging is required. Computed Tomography (CT) is the current imaging modality of choice. In our retrospective data, CT-scans showed a sensitivity of 91,7% and specificity of 100% for diagnosis of major complications, this is conformed in literature. Moreover, in the study conducted by Eckmann et al. CT-scan imaging showed a sensitivity of 97%. Another recent study established CT-scan imaging as the preferred modality in diagnosis of anastomotic leakage.
In 2008, Den Dulk et al. implemented a standardized scoring system for the clinical status of patients undergoing colorectal surgery. With this system they decreased the time between surgery and diagnosis of anastomotic leakage from 8 to 6 days, thereby decreasing mortality from 39% to 24% (p=0,24). Further supporting the role for a standardized postoperative quality control algorithm following MAS. However the search for an optimal algorithm continues.
CRP and CT scanning have shown to be able to differentiate between uncomplicated and complicated postoperative courses. Currently their use is only on demand. The here presented PRECious protocol is a postoperative Quality Control algorithm, which aims at early diagnosis and treatment of patients with major complications.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Precious arm | Experimental | Procedure: PRECiousPostoperative controls according to the PRECious protocol, which entails standardized measurement of CRP levels on postoperative day three, four and five. If CRP levels exceed 140 mg/l additional CT-scan imaging will be conducted. |
| Control | No intervention | –Standard postoperative controls. Additional testing will only be conducted on demand. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age equal to or above 18 years
- Planned elective MAS
- Written and oral informed consent
Key exclusion criteria (5 listed)
- Acute MAS
- ASA classification equal to four or higher
- Insufficient Dutch language skills
- contrast allergies
- glomerular filtration rate (GFR) < 60 ml/min/1,73m2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PRECiousStandardized measurement of serum CRP levels on postoperative day 3,4 and 5. | Procedure or surgery | Precious arm |
Primary outcome
Morbidity and mortality after major complications
Time frame: one year
Combined Primary outcome, entailing both: 1. Mortality; during 12 month follow-up 2. Morbidity associated with major complications and after reoperation within 12 months after index operation. Including: Fistula, Wound dehiscence/incisional hernia/open abdomen, bowel obstruction or herniation, abscess, abdominal compartment syndrome, perforation of visceral organ, unplanned enterostomy, enterostomy dysfunction due to prolapse, stenosis or retraction, myocardial infarction, pulmonary embolus, respiratory insufficiency; necessitating mechanical ventilation, cerebrovascular accident, renal failure, urosepsis; urinary tract infection with positive urine and blood cultures and circulatory shock, upper GI bleeding needing intervention of any type, intra-abdominal bleeding, anastomotic leak after relaparotomy
5 secondary outcomes
Quality of life questionnaires
Time frame: 3,5 days, 3 and 12 months postoperatively
Add-on value of CRP
Time frame: postoperative days 3,4 and 5
Length of stay
Time frame: Up to one year after randomization
Length of Intensive Care admission
Time frame: up to one year after randomization
Cost-efficiency
Time frame: one year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2020.
- Derived from this study: PubMed 26314740Straatman J, Cuesta MA, Schreurs WH, Dwars BJ, Cense HA, Rijna H, Sonneveld DJ, den Boer FC, de Lange-de Klerk ES, van der Peet DL. The PRECious trial PREdiction of Complications, a step-up approach, CRP first followed by CT-scan imaging to ensure quality control after major abdominal surgery: study protocol for a stepped-wedge trial. Trials. 2015 Aug 28;16:382. doi: 10.1186/s13063-015-0903-y.
Related trials for Postoperative Complications
Recruiting
Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area
Anastomotic Leaks, Hartmanns Stump Leakage
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Not yet recruiting
Bispectral Index-Guided Propofol Sedation During Endoscopic Retrograde Cholangiopancreatography
Deep Sedation, Endoscopic Retrograde Cholangiopancreatography
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jennifer Straatman, MD principal investigator
VU Medisch Centrum
Donald van der Peet, MD, PhD principal investigator
VU Medisch Centrum
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PRECious in people with Postoperative Complications, run by Amsterdam UMC, location VUmc at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Morbidity and mortality after major complications (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02102217, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2020.